A research group led by Professor Toshiaki Furukawa of Kyoto University comprehensively describes the characteristics of 522 drugs from the results of past 21 clinical trials that directly compared the efficacy and side effects of first and second generation antidepressants. We conducted a study to compare and evaluate, and reported the results.
It is said that 3% to 16% of the world's population will experience depression in their lifetime, and the number of patients is increasing, and it is thought that this tendency will continue in the future.Treatment is often with antidepressants, but a comprehensive and direct comparison of dozens of drugs that have been developed and put into practical use, such as which drugs are effective and how likely they are to cause side effects. There was no.
On the other hand, since many clinical studies have been conducted all over the world that directly compare the effects and frequency of side effects of several antidepressants, this study integrates these past research data and conducts clinical studies. Then, I tried to compare drugs that were not directly compared.
The collected research results, including those not published, amount to 2016 studies reported by January 1, 8, for a total of 522 trials.As a result of the analysis, the 116,477 drugs targeted this time have a wide range of discontinuation rates due to the ease of appearance of effects and side effects, and 21 antidepressants such as amitriptyline and escitalopram are particularly effective. It was clarified that the six drugs including the drug are relatively unlikely to cause side effects.
The results of this study are considered to be important reference information for advancing dosing treatment based on evidence as well as the personal experience and impression of doctors.The research group says that it is necessary to continue to accumulate similar evidence not only for the first and second generation antidepressants dealt with in this study, but also for drugs that will be developed in the future.
